Translations:Ethyl eicosapentaenoic acid/19/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
FuzzyBot (talk | contribs)
Importing a new version from external source
 
(No difference)

Latest revision as of 19:16, 15 April 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (Ethyl eicosapentaenoic acid)
==Mechanism of action==
Eicosapentaenoic acid (EPA), the active metabolite of ethyl eicosapentaenoic acid (E-EPA), like other omega-3 fatty acid based drugs, appears to reduce production of triglycerides in the liver and to enhance clearance of triglycerides from circulating [[very low-density lipoprotein]] (VLDL) particles. The way it does that is not clear, but potential mechanisms include increased [[Beta oxidation|breakdown of fatty acids]]; inhibition of [[diglyceride acyltransferase]], which is involved in biosynthesis of triglycerides in the liver; and increased activity of [[lipoprotein lipase]] in blood.

Mechanism of action

Eicosapentaenoic acid (EPA), the active metabolite of ethyl eicosapentaenoic acid (E-EPA), like other omega-3 fatty acid based drugs, appears to reduce production of triglycerides in the liver and to enhance clearance of triglycerides from circulating very low-density lipoprotein (VLDL) particles. The way it does that is not clear, but potential mechanisms include increased breakdown of fatty acids; inhibition of diglyceride acyltransferase, which is involved in biosynthesis of triglycerides in the liver; and increased activity of lipoprotein lipase in blood.